In vitro exploration of a myeloid-derived suppressor cell line as vehicle for cancer gene therapy

Article metrics

Abstract

Recent research indicates that cell-mediated gene therapy can be an interesting method to obtain intratumoral expression of therapeutic proteins. This paper explores the possibility of using transfected myeloid-derived suppressor cells (MDSCs), derived from a murine cell line, as cellular vehicles for transporting plasmid DNA (pDNA) encoding interleukin-12 (IL-12) to tumors. Transfecting these cells via electroporation caused massive cell death. This was not due to electroporation-induced cell damage, but was mainly the result of the intracellular presence of plasmids. In contrast, pDNA transfection using Lipofectamine 2000 (LF2000) did not result in a significant loss of viability. Differences in delivery mechanism may explain the distinctive effects on cell viability. Indeed, electroporation is expected to cause a rapid and massive influx of pDNA resulting in cytosolic pDNA levels that most likely surpass the activation threshold of the intracellular DNA sensors leading to cell death. In contrast, a more sustained intracellular release of the pDNA is expected with LF2000. After lipofection with LF2000, 56% of the MDSCs were transfected and transgene expression lasted for at least 24 h. Moreover, biologically relevant amounts of IL-12 were produced by the MDSCs after lipofection with an IL-12 encoding pDNA. In addition, IL-12 transfection caused a significant upregulation of CD80 and considerably reduced the immunosuppressive capacity of the MDSCs. IL-12-transfected MDSCs were still able to migrate to tumor cells, albeit that lipofection of the MDSCs seemed to slightly decrease their migration capacity.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

References

  1. 1

    Talmadge JE, Gabrilovich DI . History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13: 739–752.

  2. 2

    Eisenstein S, Coakley Ba, Briley-Saebo K, Ma G, Chen HM, Meseck M et al. Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res 2013; 73: 5003–5015.

  3. 3

    Basel MT, Shrestha TB, Bossmann SH, Troyer DL . Cells as delivery vehicles for cancer therapeutics. Ther Deliv 2014; 5: 555–567.

  4. 4

    Podhajcer OL, Lopez MV, Mazzolini G . Cytokine gene transfer for cancer therapy. Cytokine Growth Factor Rev 2007; 18: 183–194.

  5. 5

    Scanlon KJ . Cancer gene therapy: challenges and opportunities. Anticancer Res 2004; 24: 501–504.

  6. 6

    Hu YL, Fu YH, Tabata Y, Gao JQ . Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release 2010; 147: 154–162.

  7. 7

    Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noel D . Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 2006; 82: 1060–1066.

  8. 8

    Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC et al. Spontaneous human adult stem cell transformation. Cancer Res 2005; 65: 3035–3039.

  9. 9

    Centeno CJ, Al-Sayegh H, Freeman MD, Smith J, Murrell WD, Bubnov R . A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. Int Orthop 2016; 40: 1755–1765.

  10. 10

    Ankrum J, Karp JM . Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med 2010; 16: 203–209.

  11. 11

    De Becker A, Riet IV . Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy? World J Stem Cells 2016; 8: 73–87.

  12. 12

    Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R . Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101: 2999–3001.

  13. 13

    Mosna F, Sensebe L, Krampera M . Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem Cells Dev 2010; 19: 1449–1470.

  14. 14

    Pan PY, Chen HM, Chen SH . Myeloid-derived suppressor cells as a Trojan horse: a cellular vehicle for the delivery of oncolytic viruses. Oncoimmunology 2013; 2: e25083.

  15. 15

    Chandra D, Jahangir A, Quispe-Tintaya W, Einstein MH, Gravekamp C . Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice. Br J Cancer 2013; 108: 2281–2290.

  16. 16

    Steding CE, Wu ST, Zhang Y, Jeng MH, Elzey BD, Kao C . The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology 2011; 133: 221–238.

  17. 17

    Thaci B, Ahmed AU, Ulasov IV, Wainwright DA, Nigam P, Auffinger B et al. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther 2014; 21: 38–44.

  18. 18

    Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13: 4677–4685.

  19. 19

    Cemazar M, Jarm T, Sersa G . Cancer electrogene therapy with interleukin-12. Curr Gene Ther 2010; 10: 300–311.

  20. 20

    Liechtenstein T, Perez-Janices N, Gato M, Caliendo F, Kochan G, Blanco-Luquin I et al. A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget 2014; 5: 7843–7857.

  21. 21

    Apolloni E, Bronte V, Mazzoni A, Serafini P, Cabrelle A, Segal DM et al. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol 2000; 165: 6723–6730.

  22. 22

    Denies S, Cicchelero L, Polis I, Sanders NN . Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs. Oncotarget 2016; 7: 10905–10916.

  23. 23

    Shimokawa T, Okumura K, Ra C . DNA induces apoptosis in electroporated human promonocytic cell line U937. Biochem Biophys Res Commun 2000; 270: 94–99.

  24. 24

    Floros T, Tarhini AA . Anticancer cytokines: biology and clinical effects of interferon-alpha2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol 2015; 42: 539–548.

  25. 25

    Xu Y, Zhao W, Wu D, Xu J, Lin S, Tang K et al. Isolation of myeloid-derived suppressor cells subsets from spleens of orthotopic liver cancer-bearing mice by fluorescent-activated and magnetic-activated cell sorting: similarities and differences. Int J Clin Exp Pathol 2014; 7: 7545–7553.

  26. 26

    Heller L, Todorovic V, Cemazar M . Electrotransfer of single-stranded or double-stranded DNA induces complete regression of palpable B16.F10 mouse melanomas. Cancer Gene Ther 2013; 20: 695–700.

  27. 27

    Stacey KJ, Ross IL, Hume DA . Electroporation and DNA-dependent cell death in murine macrophages. Immunol Cell Biol 1993; 71 (Pt 2): 75–85.

  28. 28

    Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740–745.

  29. 29

    Znidar K, Bosnjak M, Cemazar M, Heller LC, Cytosolic DNA . Sensor upregulation accompanies DNA electrotransfer in B16.F10 melanoma cells. Mol Ther Nucleic Acids 2016; 5: e322.

  30. 30

    Magnusson T, Haase R, Schleef M, Wagner E, Ogris M . Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations. J Gene Med 2011; 13: 382–391.

  31. 31

    Brooks AR, Harkins RN, Wang P, Qian HS, Liu P, Rubanyi GM . Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 2004; 6: 395–404.

  32. 32

    Tolmachov OE, Subkhankulova T, Tolmachova T . Silencing of transgene expression: a gene therapy perspective. In: Martin-Molina F (ed.) Gene Therapy - Tools and Potential Applications. InTech: Rijeka, Croatia, 2013, pp 49–68.

  33. 33

    Wei LZ, Xu Y, Nelles EM, Furlonger C, Wang JC, Di Grappa MA et al. Localized interleukin-12 delivery for immunotherapy of solid tumours. J Cell Mol Med 2013; 17: 1465–1474.

  34. 34

    Zhang L, Morgan Ra, Beane JD, Zheng Z, Dudley ME, Kassim SH et al. Tumor infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res 2015; 21: 2278–2288.

  35. 35

    Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011; 121: 4746–4757.

  36. 36

    Manzotti CN, Liu MK, Burke F, Dussably L, Zheng Y, Sansom DM . Integration of CD28 and CTLA-4 function results in differential responses of T cells to CD80 and CD86. Eur J Immunol 2006; 36: 1413–1422.

  37. 37

    Denies S, Cicchelero L, Van Audenhove I, Sanders NN . Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. J Control Release 2014; 187: 175–182.

  38. 38

    Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G . S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 2011; 9: 133–148.

  39. 39

    Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D . S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 2006; 312: 184–197.

  40. 40

    Zheng R, Chen S, Chen S . Correlation between myeloid-derived suppressor cells and S100A8/A9 in tumor and autoimmune diseases. Int Immunopharmacol 2015; 29: 919–925.

  41. 41

    Garcia-Hernandez ML, Hernandez-Pando R, Gariglio P, Berumen J . Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology 2002; 105: 231–243.

  42. 42

    Uekusa Y, Gao P, Yamaguchi N, Tomura M, Mukai T, Nakajima C et al. A role for endogenous IL-12 in tumor immunity: IL-12 is required for the acquisition of tumor-migratory capacity by T cells and the development of T cell-accepting capacity in tumor masses. J Leukoc Biol 2002; 72: 864–873.

  43. 43

    Rabinowich H, Herberman RB, Whiteside TL . Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells. Cell Immunol 1993; 152: 481–498.

Download references

Acknowledgements

This work was supported by grants of the University of Ghent (BOF) and by grants from the research foundation—Flanders (FWO; G.0235.11N and G.0621.10N). FC is a fellow of the research foundation—Flanders (FWO).

Author information

Correspondence to N N Sanders.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on Cancer Gene Therapy website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading